Resultados de la búsqueda por Farley,MM
Actualizar mis citas con la selección
1 a 13 de 13
Presentar
resultados
Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, Wilson LE, Holzbauer SM, Phipps EC, Dumyati GK, Beldavs ZG, Kainer MA, et al..
Trends in U.S. burden of Clostridioides difficile infection and outcomes.
N Engl J Med 2020;382:2 de abril. [Ref.ID 103578]
Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Méek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC.
Burden of Clostridium difficile infection in the United States.
N Engl J Med 2015;372:825-34. [Ref.ID 98811]
4.
Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, Farley MM, Jorgensen JH, Lexau CA, Petit S, Reingold A, Schaffner W, Thomas A, Whitney CG, Harrison LH.
Effect of pneumococcal conjugate vaccine on pneumococcal meningitis.
N Engl J Med 2009;360:244-56. [Ref.ID 85015]
Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist A-C, Gershman KA, Vázquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A.
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.
Lancet 2006;368:1495-502. [Ref.ID 78392]
Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG, for Active Bacterial Core Surveillance of the Emerging Infections Program Network.
Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.
N Engl J Med 2006;354:1455-63. [Ref.ID 76657]
Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, Harriman K, Harrison LH, Lynfield R, Farley MM, for the Active Bacterial Core Surveillance Program of the Emerging Infections Program Network.
Methicillin-resistant Staphylococcus aureus disease in three communities.
N Engl J Med 2005;352:1436-44. [Ref.ID 73339]
Stephens DS, Zughaier SM, Whitney CG, Baughman WS, Barker L, Gay K, Jackson D, Orenstein WA, Arnold K, Schuchat A, Farley MM, and the Georgia Emerging Infections Program.
Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment.
Lancet 2005;365:855-63. [Ref.ID 73007]
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, for the Active Bacterial Core Surveillance of the Emerging Infections Program Network.
Decline in invasive pneumococcal disease after the introduction of protein - polysaccharide conjugate vaccine.
N Engl J Med 2003;348:1737-46. [Ref.ID 65954]
Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A, for the Active Bacterial Core Surveillance Program on the Emerging Infections Program Network.
Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.
N Engl J Med 2000;343:1917-24. [Ref.ID 54548]
Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia D J, Lexau C, Stefonek KR, Patterson J E, Jorgensen JH.
Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-97.
Am J Public Health 2000;90:223-9. [Ref.ID 49246]
Actualizar mis citas con la selección
1 a 13 de 13